Open an account

Lisata Therapeutics

LSTA · NASDAQ

$1.04+$0.04 (+4.00%)TodayMarket closed ·
Prev close $1.00

About LSTA

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 21 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Employees
21
Headquarters
Basking Ridge, New Jersey
Listed
Nov 3, 1995
Sector
Health Care
Industry
Biotechnology
Website
lisata.com

LSTA key statistics

Market cap
9.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
122.45K
Volume
113.74K
Open price
$1.01
High today
$1.08
Low today
$0.996
52 Week high
$5.07
52 Week low
$0.9604

Lisata Therapeutics (LSTA) at a glance

As of Oct 20, 2026, Lisata Therapeutics (LSTA) shares are priced at $1.04, giving the company a market cap of 9.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.996 and $1.08. The current price is 4.4% above the day's low and 3.7% below its high.

Volume so far is 113.74K shares, in line with the average of 122.45K shares a day.

Over the past year Lisata Therapeutics has ranged from $0.9604 to $5.07, and now sits 2% of the way up that range.

Lisata Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY25 it reported -$0.49 per share against an estimate of -$0.5457.

The average analyst price target is $15.30, 1371.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $15.30
Low
$15.15
Now
$1.04
High
$15.75

LSTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 20.2% on average.

  1. Q4 FY23: reported -$0.66 per share against an estimate of -$0.9078
  2. Q1 FY24: reported -$0.65 per share against an estimate of -$0.7395
  3. Q2 FY24: reported -$0.61 per share against an estimate of -$0.7752
  4. Q3 FY24: reported -$0.59 per share against an estimate of -$0.765
  5. Q4 FY24: reported -$0.55 per share against an estimate of -$0.7752
  6. Q1 FY25: reported -$0.55 per share against an estimate of -$0.5406
  7. Q2 FY25: reported -$0.54 per share against an estimate of -$0.663
  8. Q3 FY25: reported -$0.49 per share against an estimate of -$0.5457

LSTA news

  • Press releasePRNewswire

    EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA

  • Vandana Singh

    Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

  • Tanya Rawat

    Lisata Therapeutics Stock Falls After Hours: Here's Why

  • Press releasePRNewswire

    Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

  • Press releasePRNewswire

    Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Similar companies

Companies in the same industry as Lisata Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.